Dr. Mary Claire Haver on Women's HRT: What She Has Said About Medication

Who Is Dr. Mary Claire Haver?

Dr. Mary Claire Haver is a board-certified OB-GYN based in Texas who completed her residency at the Louisiana State University Health Sciences Center. She founded The Pause Life, a digital education and telehealth platform focused on menopause, and authored "The Galveston Diet," which reached the New York Times bestseller list. Her social media presence, exceeding five million combined followers across Instagram and TikTok, has positioned her as one of the most influential physician voices in the menopause-care conversation in the United States.

Her Clinical Background

Haver's clinical work centers on the intersection of nutrition, inflammation, and hormonal change during the menopause transition. She completed additional training in culinary medicine and has spoken at the annual meeting of The Menopause Society (formerly NAMS). Her public statements are traceable to specific interviews, podcasts (including appearances on the Huberman Lab podcast and her own "The Pause Life Podcast"), and verified social media posts.

Why Her Medication Statements Matter

Physician-influencers occupy a unique position: their personal disclosures carry implicit clinical authority. When Haver states publicly that she uses HRT, that statement reaches millions of women who may be weighing the same decision. Treating her statements with the same factual rigor applied to any clinical source is the standard this article follows.

What Dr. Haver Has Said About HRT Publicly

Dr. Haver has been explicit and consistent: she personally uses hormone replacement therapy and prescribes it frequently in her practice. In a widely shared 2023 interview on the Huberman Lab podcast, she stated that she began HRT during perimenopause and described it as one of the most important health decisions she has made. These statements are self-reported and have not been independently verified by HealthRX beyond the public record.

Her Stated Regimen (Self-Disclosed)

In public appearances, Haver has described using transdermal estradiol (patch or gel formulation) combined with oral micronized progesterone (brand name Prometrium in the United States). She has emphasized the transdermal route specifically because absorption bypasses first-pass hepatic metabolism, a pharmacokinetic distinction supported in the literature.

Transdermal estradiol avoids the pro-thrombotic effect associated with oral estrogen. A 2010 observational study published in BMJ (N=80,396 women) found that oral estrogen was associated with increased venous thromboembolism risk, whereas transdermal estradiol was not [1]. Haver cites this pharmacokinetic rationale explicitly in her public educational content, aligning her messaging with published evidence.

Oral micronized progesterone (100 mg or 200 mg nightly) is the progestogen she references most often, consistent with data showing a more favorable cardiovascular and breast-tissue profile compared with synthetic progestins. The E3N cohort study (N=80,377) found that combined estrogen plus micronized progesterone was not associated with increased breast cancer risk at 5 years of use, unlike combinations using synthetic progestins [2].

Her Statements on Timing and the "Window of Opportunity"

Haver frequently invokes what researchers call the "timing hypothesis" or "critical window hypothesis," the concept that HRT initiated within 10 years of menopause onset or before age 60 carries the most favorable risk-benefit ratio. The Kronos Early Estrogen Prevention Study (KEEPS, N=727) examined women aged 42 to 58 within 36 months of their last menstrual period and found no increase in carotid intima-media thickness progression in the estradiol groups versus placebo [3]. Haver cites KEEPS and the Danish Osteoporosis Prevention Study (DOPS, N=1,006) in her public talks to support early initiation.

The DOPS trial showed that women randomized to HRT within 2 years of menopause had a significantly lower rate of the composite endpoint of mortality, heart failure, and myocardial infarction after 10 years of follow-up (relative risk 0.48, 95% CI 0.26 to 0.87, P<0.05) [4]. This is a specific datum Haver has cited by name in podcast appearances.

The Evidence Base She Relies On

The Women's Health Initiative: Her Re-Framing

Haver has spent considerable public effort explaining why the original 2002 Women's Health Initiative (WHI) publication was misinterpreted. The WHI enrolled women with a mean age of 63, most of whom were more than 10 years past menopause onset. The absolute risk increase for breast cancer in the estrogen-plus-progestin arm was 8 additional cases per 10,000 woman-years, a small absolute number that Haver contrasts with the larger absolute benefits seen in younger, healthier women [5].

The 2013 re-analysis by Manson et al. In JAMA (WHI re-analysis, N=27,347) stratified outcomes by age and time since menopause. Women aged 50 to 59 who used conjugated equine estrogen showed a non-significant trend toward reduced total mortality and a significant reduction in coronary heart disease composite score [6]. This is the paper Haver references most consistently when discussing cardiovascular risk.

NAMS 2022 Position Statement

The Menopause Society's 2022 position statement concludes: "For women aged younger than 60 years or within 10 years of menopause onset and with no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [7] Haver quotes this conclusion almost verbatim in her social media posts and has tagged the NAMS organization directly on multiple occasions.

The 2022 statement also confirms that hormone therapy remains the most effective treatment for vasomotor symptoms, reducing hot flash frequency by 75% in clinical trials compared with roughly 25% for placebo [7].

Bone Density and Fracture Data

Haver frequently discusses skeletal health as an underappreciated benefit of HRT. The WHI fracture sub-study showed that combined HRT reduced hip fracture risk by 34% (hazard ratio 0.66, 95% CI 0.45 to 0.98) in women aged 50 to 79 [8]. The North American Menopause Society notes that estrogen therapy is FDA-approved for prevention of postmenopausal osteoporosis [9].

Estrogen suppresses osteoclast activity by reducing RANK-L expression, a mechanism distinct from bisphosphonates. This makes HRT a two-for-one intervention in symptomatic women: symptom relief plus skeletal protection, a framing Haver uses repeatedly.

What She Says About Who Should and Should Not Use HRT

Candidates She Describes as Appropriate

Haver has described the following profile as a reasonable candidate for HRT in her public content: a woman in perimenopause or within 10 years of her final menstrual period, under age 60, without a personal history of estrogen-receptor-positive breast cancer, without active venous thromboembolism, and without unexplained vaginal bleeding. This broadly mirrors The Menopause Society 2022 contraindication list [7].

She is careful to distinguish between absolute contraindications, such as current hormone-sensitive cancers, and relative contraindications that require shared decision-making. Controlled hypertension, a history of benign breast disease, and a family history of breast cancer are examples she places in the shared-decision category rather than the absolute-contraindication category.

Contraindications She Consistently Emphasizes

Haver has been consistent on one point: women with a personal history of estrogen-receptor-positive breast cancer should not initiate HRT without oncology involvement. She has repeated this across platforms, distinguishing her advocacy from blanket promotion. She also notes that women with a BRCA1 or BRCA2 mutation face a genuinely different risk calculus requiring specialist input.

Active liver disease is another contraindication she names, reinforcing that transdermal delivery (which bypasses hepatic first-pass metabolism) is not automatically safe in women with hepatic impairment, because systemic estrogen still affects hepatic protein synthesis.

Her Stance on Specific Medications and Delivery Routes

Transdermal Estradiol

Haver consistently recommends transdermal over oral estradiol for most patients, citing the thrombosis data from the 2010 BMJ study [1] and a 2016 analysis in the British Journal of Clinical Pharmacology showing that transdermal estradiol does not activate hepatic coagulation factor synthesis to the same degree as oral forms [10]. She uses patch or gel formats interchangeably in her public discussions, noting that individual absorption variability sometimes favors one over the other.

Serum estradiol targets she has mentioned in public content range from 50 to 150 pg/mL for symptom control, consistent with the dosing guidance in the NAMS clinical practice guidelines [7]. She advises against chasing a specific number in isolation; symptoms and quality of life are co-equal endpoints in her framework.

Oral Micronized Progesterone

Haver distinguishes carefully between progesterone (the bioidentical hormone) and progestogens or synthetic progestins such as medroxyprogesterone acetate (MPA). The WHI used MPA, not micronized progesterone. She references the E3N cohort data [2] and a 2008 study in Climacteric showing that micronized progesterone does not impair the beneficial effect of estrogen on endothelial function, unlike MPA [11].

For women who have had a hysterectomy, she notes that progestogen is unnecessary because endometrial protection is not required in the absence of a uterus. Estrogen alone is appropriate in that population, a point supported by the estrogen-only arm of the WHI, which showed a reduction in breast cancer incidence (hazard ratio 0.77, 95% CI 0.59 to 1.01) after 13 years of follow-up [12].

Testosterone in Women

Haver has discussed androgen therapy for women in several podcast appearances, specifically low-dose testosterone for hypoactive sexual desire disorder (HSDD) and fatigue symptoms. She references the Global Consensus Position Statement on testosterone use in women, published simultaneously in four journals in 2019, which concluded that testosterone therapy improves sexual function in postmenopausal women [13]. She notes that FDA-approved testosterone products for women do not exist in the United States, meaning any prescription is off-label and requires compounding or off-label use of male-formulated products at lower doses.

Haver is careful to separate testosterone from "energy optimization" claims that lack the same evidence base. Her public statements on testosterone remain anchored to HSDD outcomes, not general performance enhancement.

DHEA and Prasterone

In educational content on The Pause Life, Haver has discussed intravaginal DHEA (prasterone, brand name Intrarosa), FDA-approved in 2016 for moderate-to-severe dyspareunia due to menopause-related vulvovaginal atrophy [14]. She positions it as an option for women who cannot or choose not to use systemic estrogen but want effective local treatment beyond low-dose vaginal estrogen.

Her Criticism of Under-Treatment in Clinical Practice

The "Menopause Gap" She Describes

Haver has been pointed in her criticism of what she calls a systemic gap in menopause care, noting that many OB-GYN residency programs historically allocated fewer than two hours of curriculum time to menopause medicine. A 2019 survey published in Menopause (the journal of The Menopause Society) found that fewer than 20% of OB-GYN residents felt adequately trained to manage menopause [15]. Haver cites this data repeatedly when arguing that physician hesitancy about HRT stems partly from training gaps rather than evidence.

Her Framing of the WHI "Fallout"

Haver describes the post-2002 period as one in which HRT prescriptions dropped sharply. Data from the CDC and IMS Health confirmed that combined HRT prescriptions fell approximately 66% between 2001 and 2004 following the WHI publication [16]. She argues that this overcorrection left a generation of women without an effective treatment for vasomotor symptoms, genitourinary syndrome of menopause, and bone loss, and that the subsequent rise in osteoporosis-related fracture rates in women has been an underappreciated cost.

What Inference Requires Labeling

The following points are inference or extrapolation from her public pattern of statements rather than direct quotations. They are labeled clearly as such.

Haver has not published a formal clinical protocol for The Pause Life's prescribing practices, so the specific titration steps she uses clinically are not verifiable from public sources. Her social media posts reflect educational content, not individualized prescriptions. The dosing ranges she mentions publicly (e.g., estradiol 50 to 100 mcg/day transdermal) are consistent with standard clinical practice but should not be taken as a personally tailored recommendation.

She has not publicly disclosed the specific brand of transdermal estradiol she personally uses, only the delivery route. Whether she uses a patch (e.g., Vivelle-Dot, Climara) or a gel (e.g., Estrogel, Divigel) in her own regimen is not confirmed in any traceable public source as of the date of this article.

Clinical Takeaways Grounded in the Evidence She Cites

The body of evidence Haver draws on is real, peer-reviewed, and well-regarded. Readers seeking to apply this evidence should review it in consultation with a qualified clinician who can assess individual risk factors. The key trials she references include:

• WHI re-analysis (Manson et al., JAMA, 2013) [6]: age-stratified outcomes
• DOPS (Schierbeck et al., BMJ, 2012) [4]: cardiovascular outcomes with early initiation
• KEEPS (Harman et al., Ann Intern Med, 2014) [3]: carotid IMT with early HRT
• E3N cohort (Fournier et al., Breast Cancer Res Treat, 2008) [2]: breast cancer risk by progestogen type
• NAMS 2022 position statement [7]: current clinical guidance

Women aged <60 or within 10 years of menopause onset without contraindications should ask their clinician specifically about transdermal estradiol plus oral micronized progesterone as a first-line option, as supported by the NAMS 2022 statement and the pharmacokinetic evidence for transdermal delivery [1][7].